Product Name:
ASK1-pT838
Product Number:
ab-pk526
Target Full Name: Apoptosis signal regulating protein-serine kinase 1
Target Alias: Apoptosis signal regulating kinase 1; Apoptosis signal-regulating kinase 1; ASK-1; Kinase ASK1; M3K5; MAP3K5; MAPK/ERK kinase kinase 5; MAPKKK5; MEK kinase 5; MEKK5; ENSG00000197442
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK525
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T838
Protein UniProt: Q99683
Protein SigNET: Q99683
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ASK1 (MAP3K5) sequence peptide Cat. No.: PE-04ALO99
Antibody Immunogen Sequence: TE(pT)FTG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues T836 to G841; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues T836 to G841; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 150-160 kDa.
Related Product 1: ASK1-pT838 blocking peptide
Scientific Background: ASK1 (MAP3K5, MAPKKK5) is a protein-serine/threonine kinase that is a member of the STE group of protein kinases in the STE11 family. This kinase is moderate to highly expressed in most tested human tissues. ASK1 regulates apoptosis through mitochondria-dependent caspase activation. Overexpression of ASK1 induces apoptotic cell death. ASK1 interacts with members of the TRAF family and is activated by TRAF2 in the tumour necrosis factor-alpha (TNF) signalling pathway. ASK1 is activated by phosphorylation at T838 by MAP3K6 and inhibited by phosphorylation at S966 and S1033. It acts as an upstream activator of the MKK>JNK and MKK>p38 MAPK signal transduction cascades through the direct phosphorylation of different MAP kinases, such as MAP2K4 (MKK4), MAP2K3 (MKK3), MAP2K6 (MKK6), and MAP2K7 (MKK7). It is dephosphorylated and activated by PGAM5. ASK1 contains an N-terminal autoinhibitory domain. It is inhibited by phosphorylation at S966 and S1033, and by HIV-1 Nef. ASK1 appears to be a tumour suppressor protein (TSP) as the active form of the protein kinase normally acts to inhibit tumour cell proliferation. 24% of melanoma cell lines were found to contain mutations in the coding-regions of either MAP3K5 or the closely related kinase MAP3K9, often in the kinase catalytic domain.Loss of heterozygosity in MAP3K5 was observed in 85% of melanoma specimens, indicating that the previously observed mutations result in the loss-of-function in the protein. An I780F substitution, the most commonly observed mutant form of the kinase, inhibits phosphotransferase activity.